Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 9/20 | 0.50 |
| ▸ | CDK4 | P11802 | 6/20 | 0.50 |
| ▸ | CCND1 | P24385 | 6/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.50 |
| ▸ | CDK1 | P06493 | 6/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.50 |
| ▸ | CCND3 | P30281 | 4/20 | 0.47 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.47 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5050255 | 0.86 | CDK2 (0.44) | CDK2CDK4CCND1CCNA2CCNA1 | |
| SCHEMBL24121993 | 0.84 | MAPK14 (0.48) | CDK2CDK4CCND1CCNA2CCNA1 | |
| SCHEMBL12367050 | 0.77 | CDK2 (0.56) | CDK2CDK4CCND1CCNA2CCNA1 | |
| SCHEMBL14136100 | 0.77 | DYRK1A (0.47) | CDK2CDK4CCND1CCNA2CCNA1 | |
| SCHEMBL26830431 | 0.74 | MAPK1 (0.62) | CDK2CDK4CCND1CCNA2CCNA1 | |
| SCHEMBL12965952 | 0.71 | DYRK1A (0.49) | CDK2MAPK8MAPK9MAPK10TLR8 | |
| Hydrochloric Acid SCHEMBL14877397 | 0.70 | DYRK1A (0.48) | CDK2MAPK8MAPK9MAPK10TLR8 | |
| SCHEMBL12813887 | 0.70 | PIM1 (0.47) | MAPK8MAPK9MAPK10TLR8TLR7 | |
| SCHEMBL17910154 | 0.70 | MAPK8 (0.60) | CDK2CDK4CCND1CCNA2CCNA1 | |
| SCHEMBL14887088 | 0.70 | TLR8 (0.43) | CDK2CDK4CCND1CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405220-B2 | Pyrazolopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2008-07-29 | — | — | US | claimed |
| EP-1758871-B1 | PYRAZOLO PYRIMIDINES | HOFFMANN LA ROCHE (CH) | 2007-11-14 | — | — | EP | claimed |
| US-20050277655-A1 | e.g. [3-(2-Methoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]-phenyl-amine; cyclin-dependent kinase (Cdk1, 2, 4) inhibitor; anticarcinogenic agent; breast, lung, colon and prostate solid tumors | DING QINGJIE | 2005-12-15 | — | — | US | claimed |
| US-7405220-B2 | Pyrazolopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405220-B2 | Pyrazolopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1758871-B1 | PYRAZOLO PYRIMIDINES | HOFFMANN LA ROCHE (CH) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277655-A1 | e.g. [3-(2-Methoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]-phenyl-amine; cyclin-dependent kinase (Cdk1, 2, 4) inhibitor; anticarcinogenic agent; breast, lung, colon and prostate solid tumors | CDK1, CDK4, CDK2 | CDK2 3/4885CDK4 2/4885CCND1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.